Cancer Therapy–Related Hypertension
Published: January 09, 2023
- Anti-cancer drugs have improved cancer survival, but they come with cardiovascular toxicities that can cause incident heart disease, thromboembolic disease and hypertension or they may exacerbate current underlying conditions.
- One of the most common side effects is hypertension, most notably seen in vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors and proteasome inhibitors.
- This AHA scientific statement advocates for the team approach to manage these complex patients including oncologists, cardiologists, hypertension specialists, primary care providers and pharmacists.
Supporting Materials
Recommended Reading
- Cardio-Oncology Drug Interactions
- Cardio-Oncology: Vascular and Metabolic Perspectives
- Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology
- Weight-Loss Strategies for Prevention and Treatment of Hypertension
- Resistant Hypertension: Detection, Evaluation, and Management